Filed by Vireo Growth Inc. pursuant to
Rule 425 under the Securities Act of 1933, as
amended
and deemed filed pursuant to Rule 14a-6
of the Securities Exchange Act of 1934, as amended
Subject Company: Planet 13 Holdings Inc.
Commission File No. 000-56374
Date: November 17, 2026
As previously disclosed, on July 26, 2026, Vireo Growth Inc., a British
Columbia corporation ("Vireo"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Planet
13 Holdings Inc., a Nevada corporation ("Planet 13"), and Supernova Merger Sub Inc., a Nevada corporation and a wholly owned
subsidiary of Vireo ("Merger Sub"), pursuant to which Vireo will, as a result of the merger contemplated thereby, acquire all
of the issued and outstanding equity interests of Planet 13 (the "Merger").
On November 16, 2026, Sam Armenia, Vireo’s Director of Capital
Markets, participated in a recorded interview with Jay Rosenthal and Jeremy Burke on Cultivated Live, which was made publicly available
on November 17, 2026. A transcript of the interview is set forth below.
Transcript
INTERVIEW WITH CULTIVATED LIVE – NOVEMBER
16, 2026
Jay Rosenthal, Cultivated: Welcome to Cultivated Live. I am
Jay Rosenthal. Over there is Jeremy Burke, and in the middle is Sam Armenia. Now, I didn't even get to- I pronounced that correctly, from
Vireo, which I'm also pronouncing correct right now. Um, Sam, um, you and I are in Toronto. Jeremy is in New York- Yeah ... but, uh- Yeah
... I didn't realize you lived in Toronto, but then I saw the Jays hat, and there aren't that many people that wear Jays hats south of
the border.
But certainly north of the border it is, uh, it's part of the uniform,
yeah?
Sam Armenia, Vireo Growth: It is surprising s- though, when
I, when I go to the US for, like, conferences and stuff how people will see my Jays hat and say something. Vlad, he's kind of, I think
he transcends the border, right? Yeah.
Jay Rosenthal, Cultivated: He does.
Jeremy Berke, Cultivated: And, and, you know, we almost took
down the evil empire in the Dodgers, so- Yeah
there was there was a way of-
Jay Rosenthal, Cultivated: That seems
Jeremy Berke, Cultivated: like- ... people wearing Jays hats.
Jay Rosenthal, Cultivated: Seems like a
Sam Armenia, Vireo Growth: very distant- We, we did. We, in,
in our minds we did, right?
Jay Rosenthal, Cultivated: It's very distant, dist- very distant-
This, this much ... at this point. Very, yeah, this much-
Sam Armenia, Vireo Growth: Yeah, no kidding ...
Jay Rosenthal, Cultivated: a year ago. Um- Yeah.
Sam Armenia, Vireo Growth: Yeah. Yeah ...
Jay Rosenthal, Cultivated: uh, we're gonna talk about Vireo,
where you guys are, what you're doing, but give us a little, uh, this is the question Jeremy likes to ask, so I'll steal it from him.
Give us a little bit about your background, C21, how you got to the
cannabis industry, and then we'll jump in
Sam Armenia, Vireo Growth: Cool. Well, thanks for having me,
guys. Um, my background is an interesting one. It was not, uh, intended to be in cannabis. I, um, I was a spatial analyst before in previous...
I was actually started in film and television way back.
I'm an old guy now, guys. So, um- Yeah. ... way back in the day, I
was CBC Sports, and then I was on Hollywood films and, uh, kind of have two film degrees, and then I transitioned to kind of, uh, spatial
analysis. Uh, I was always kind of, um, interested in, in kind of big spatial data analysis, so that's kind of how I bridged to finance.
Um, and what happened is I got in a really bad accident up here in
Toronto in 2012. I was hit on the 401, uh, spinal injury. Wow. I've told this story before, but, um, took years of rehab to kind of get
back on my feet. Um, and I was looking for an alternative to kind of opioid kind of pain management, uh, options at the time.
So I started, you know, some people kind of recommended cannabis as
an option. This is when Canada was just, you know, it was medical, but it was considering, um, adult use. And so I started kind of investigating
and, uh, learning more about the plant and then, you know, this rush, the Ca- the Canadian gold rush kind of happened, right?
Where it's just like, oh, I'll start investing in the space too, 'cause
now I'm interested in it. And, uh, before you knew it, I, I joined C21. Um, I was on X way back, like I'm, I'm kind of OG on sharing-
... cannabis analysis, if you go way back like a decade, and I was sharing like comp tables. It's a funny story because C21 came to me
with a comp table, 'cause I was talking about C21 on, on Twitter back then, and they shared a comp table with me and they said, "Did
you see Canaccord's comp table?"
And I said, "That's my comp table." Like, "You see the
water stamp?" "That's mine." They said, "Well, Canaccord gave it to us. We thought it was theirs." So they were
impressed, and they kind of brought me on, uh- Interesting ... you know, seven, eight years later. Um, you know, we built one of the best,
you know, s- single state small operators, uh, the only one that paid off its senior debt in the industry.
Um, you know, we were always, I would say, balance sh- balance sheet
constrained at C21. You know, we were never flush with cash. I think, you know, when I joined, we had 2 million of cash in 2019, and when,
you know, when we sold, we had 2 million of cash. Like we, we never had- Yeah ... much of a buffer, but we generated so much significant
free cash that, you know, we paid off the 30 million senior debt, and we, you know, expanded cultivation and we, you know, we bought um,
a, a, one of the Deep Root stores before Deep Root sold to Vireo, um, and kind of scaled that, uh, very successfully.
And, you know- Our, our limitations were, you know, being capital constrained,
um, especially given the currencies where they are in the industry, you know, what can you really do in terms of, you know, continued
growth and expansion? We had three of the best performing stores in the state, but how much more can you get out of, you know, especially
Nevada, which was ha- has been a declining state for, for years now, since kind of the COVID stay-at-home stimulus highs of the industry.
I think it's down, like, 30 or 40% in revenue as a state. Right. And,
you know, C21 was always kind of bucking that trend. We were always, you know, at least finding a way to mitigate and, and, you know.
But ultimately as the industry started to see some, uh, you know, progressive change or hopeful change with regulatory, uh, especially
once the executive order happened, uh, December, uh, last year, you know, it became apparent that we needed to join, uh, you know, with
one of the large operators to kind of, you know, continue our story.
And so, you know, we, we weighed all our options. Um, you know, I don't
know if you guys ever read the circular but, you know, we, we outlined- Yeah ... that we had, you know, multiple options and, you know,
we ultimately landed on Vireo because we think it has the best growth trajectory in the industry. Um, and, you know, philosophies were
aligned and, you know, I think it's a misunderstood story in the s- in the sector still, but one that is, you know, obviously the fastest
growing, uh, company in the industry considering, you know, the, the M&A consolidation, uh, that has taken place.
We're now at 17 deals in the last, you know, 22 months or something
like that. So it's, it's just- Right ... significant. And, you know, it's, it's a show me story, um, because, you know, M&A has been
somewhat of a, you know, mixed, uh, bag of success, to say it, you know, politely. Um, you know, most M&A deals have failed in the,
in the industry to date.
That being said, most of the deals, if you think back to 2020, '21,
when a lot of the M&A was happening, it was happening at cycle highs. The, the, you know- Mm-hmm ... the multiples that were being
paid on those deals were, you know, extravagant. Um, and so we think the time is now to be consolidating the industry.
Obviously, we are trading at a significantly, uh, low multiple at this
time, but we're finding, you know, creative ways to structure these deals. Um, you know, we priced most of the deals at, you know, 15
to $18 US, um, and we're trading at, like, six bucks right now. Uh, so, you know, it's, it's a challenge obviously, when your currency's,
uh, suffering to, you know, continue the, the pace that we've been on.
But we, we feel like we have the right, um, you know, we have the right
balance sheet to pull this off. We have the, the right pipeline of deals and, you know, we, we believe that we've done really smart M&A.
And, you know, the number that I would lead with this off of our Q3 numbers that we reported last week was, is the 75%, uh, gap revenue,
uh, per share growth- Mm-hmm year over year. Uh, second place in the industry is something like 17%. So when people kinda say, "Well,
it's easy to buy revenue," and anybody can do it, you know, anybody can do this M&A strategy, that's actually not correct, uh,
because most people don't have the balance sheets to, to do this. Um, but it's, you know, it's ultimately gonna be about accretive, the
accretive value that's built from these deals and, you know, it's early innings obviously.
We're s- we're still, you know, integrating a lot of these, uh, you
know, three or four of the deals haven't even closed yet, and it's gonna take us time to obviously optimize and int- integrate these businesses.
But, you know, early returns, uh, if you look at what we've done in Florida, for instance, um, or if just this overall kind of GAAP revenue,
uh, per share growth, ultimately this industry should be measured on per share kind of growth.
And yes, we need to kind of focus on earnings growth in time, but with
280, as you guys know, it kind of eats all the profit in this industry. Right. You know, we're prou- we're proud that we're already, um,
you know, pre-tax earnings, uh, positive. Um, so we reported, I think 4 million of, of nibit, uh, this quarter and, you know, our operating
income was up sus- substantially something like 17 million, uh, sequentially.
Um, you know, if you add back the one-time transaction costs that obviously
doing this much M&A, they're, they're significant at this time. Um, you know, we're kind of at an 80 million, uh, run rate for operating
income and our market cap's 300 million. So when you start to say like, you know, these guys are already starting to perform and yet the
market's obviously not, you know, um, you know, recognizing that yet.
Um, we did provide guidance, um, for both Q4 and Q1 and we provided
two different sets of numbers, uh, kind of status quo as is if no further deals close in time for those quarters to start. Obviously with
Q4 having already started, you know, n- none of those deals are gonna, are gonna be consolidated in the, in the GAAP, uh, reporting for
Q4.
We, we hope that most of the deals are, are, are captured for Q1 and,
you know, the, the guidance on Q1 should all of the deals be closed by January 1st is significant. I think our high end was the... would,
would be the highest, uh, revenue print in, in the industry's history if, you know, if we are able to close those deals in time.
So, you know, the revenue scaling, you know, significantly, um, it
was up 177% on a GAAP basis. Obviously most of that's M&A. We do have same store sales growth. Uh, it was 7% last quarter. It was
4% this quarter. Um, so you know, we feel like, uh, we're doing a really good job of, you know, integrating these a- assets quickly.
Um, you know, C21, I, where I come from, a- after the seven years,
uh, there, uh, we closed... we announced that deal in June and we closed it in August. So, you know, the, the team's ability to kind of
turn these- Right ... deals around is, is like second to none. Um, and you know, that- C21 on a financials perspective and operating,
uh, platform perspective, it was, you know, it was running Vireo on day one.
So our, our ability to kind of get there quickly is... And we have
a slide in our deck about this, um, if, if people are interested, we have a fresh deck up now as of, I think Friday So, you know, we're
really excited about our future. Um, hopefully, uh, as we prove this thesis out over time, I think people will start to, you know, to,
to get it.
But I understand where the PTSD in this industry comes from around
M&A. Sure. Yeah. Ultimately, you know, everybody wants to see organic growth, and this industry is obviously stifled, uh, both by
the intoxicating hemp, um, and also just the price compression in the majority of the states. Um, you know, so generating same-store sales
growth is obviously difficult.
We've been able to achieve that. But ultimately, you know, if you're
building value on a per share basis, whether it's inorganic through M&A or organic, it, you know, it, it all counts the same. So I,
I think that's what's being missed, uh, about our story right now and, you know, we'll continue to prove that out moving forward.
Jeremy Berke, Cultivated: So, um, Vireo closed the acquisition
for C21 in, in August, and you said, you know, in the last three months there's been, been 22 deals. That's, that's a real M&A spree,
especially in- Sevent- ... cannabis.
Sam Armenia, Vireo Growth: Yeah, 17
Jeremy Berke, Cultivated: deals. 17 deals, yeah, uh, i- in
cannabis right now. Talk a little bit about your M&A strategy, uh, you know, how you think about targets- Yep geographically,
financially. You know, for people that are new to the Vireo story, what are you looking for and, and, and how are you sourcing these
deals?
Sam Armenia, Vireo Growth: Yeah. Well, John, our, our CEO, and
Tyson, our CFO, they have a very clear objective, which is to build scale. Um, you know, we want 100 million, uh, minimum revenue in all
of the states that we're in.
So, you know, a lot of the M&A is to kind of, is to kind of r-
reach that scale in states. If you think of Nevada, Deep Roots was already one of the leading, um, operators in that state. Deep Roots
comes in from that first trio of deals that Vireo did when it kind of, when John and Tyson took over and they, they announced, uh, Deep
Roots, Proper and Wholesome.
Um, and, you know, Deep Roots is already somewhere 10 to 15% market
share in Nevada. Mm-hmm. Adding C21 kind of adds another 5%. And then, you know, Planet 13 deal's pending, so we, we'll essentially be
the largest operator in Nevada. I think we're currently at, like, 150 million run rate in that state. Um, if you look at Florida and what
we've accomplished there, you know, a lot of what we're doing is very capital efficient.
So, you know, we've already closed Fluent. The, that closed the day
before our earnings last week. Yeah. And, you know, assuming Planet 13 closes, we will have the second-largest footprint in that state
of 108 stores. If you think of what it costs to build out the, the platforms of, like, the big three or four operators in the state of
Florida versus what we've paid to acquire that kind of s- you know, scale of footprint in that state.
And, you know, so the pu- the immediate pushback would obviously be,
"Yeah, but you're buying s- you know, substandard operators or, or, or distressed operators, you know, with some- someone like Fluent."
Or Eaze Green Dragon. But that's not really the case. What it is, is these are balance sheet constrained businesses that- Hmm
you know, obviously can't optimize operations when, you know, th- when
they're over-levered. Um, and so if you look at Green Dragon closed, um, the first day of Q2, so we have two full quarters now of, uh,
Eaze in Florida, and it is the, the fastest-growing operator in the state, not just on a percentage basis, 'cause it's easy obviously
to, to have a high percentage growth if you're coming from a low base.
Right. But from a, from a total THC and total f- flower absolute growth
volume, which the OMMU, uh, you know, provides on the, on the weekly basis, um, you know, uh, Green Dragon and Fluent from Q1 to Q3 grew
s- it's something like 115 million, um, milligrams of THC was their growth, and second to that isn't even half of that.
And then on a, on a flower ounces basis, it was like 32,000 ounces
of flower, uh, in absolute kind of volume growth. So the trajectory is already, you know, started there. Uh, and we're still integrating
all these assets. Fluent just closed. We have to re-banner because in Florida you ha- you have to operate all these businesses under one
banner.
Mm-hmm. So we have to re-banner the, the Fluent stores, uh, to Eaze,
and then we'll, we'll do the same obviously when, uh, assuming, uh, Planet 13 closes. But, you know, there's kind of an opportunity as
well when you're buying these kind of distressed assets, capital constrained assets that maybe are performing, you know, below the average
of a, of a state because, you know, the opportunity to get these things right sized, to get them optimized, and to get that kind of s-
scale, um, as, you know, putting these three things together.
The other thing is in Florida, it's a unique state, obviously you have
to have the full vertical and you can't source any, you know, wholesale. Right. And so I think these three operators fit together really
well because they all were o- on a, on a cultivation produc- pro- production side of things, they were all kind of doing well in one area,
but not in others.
And so they all kind of complement each other really well. Um, and
so I think, you know, when you're a small operator in a state like Florida and you only have, you know, 100 SKUs, it's really hard to
compete to, with the big guys that have 500 SKUs. Right. But as we bring these three together, you know, we intend to ramp, uh, our s-
our s- SKU offering to kind of 500 with, you know, with the big operators.
And you know, again, we already have the second, we will have the second-largest
footprint from a store basis. So we think there's, you know, tremendous growth for us in a state like that. That's our kind of idea of
how to scale and ultimately- Yes ... it's still capital efficient because if you look at the price that we paid for these assets to get
that, you know, it's a fraction of what these operators, you know, on a de novo basis, had to build these states out.
So that's, that's the model.
Jay Rosenthal, Cultivated: Uh, I wanna ask, uh, Jeremy's the
MBA, but, um, I wanna ask a sort of MBA-type question because with the sheer number of, uh, acquisitions and the markets in which you're,
they're operating in, and the complexity, even the one you just described in Florida, of not only acquiring multiple, uh, businesses in,
um, in Florida, but multiple vertical operators in Florida- Yeah
trying to integrate. Like, what does the integration process look like
in an M&A like that, or in Nevada? Like, is there like a whole team at Vireo that is, like, integration of the deal that, like, gets
handed the portfolio once- Yeah, I
Sam Armenia, Vireo Growth: mean- ...
Jay Rosenthal, Cultivated: sort of deal, like, is done?
Sam Armenia, Vireo Growth: We have the corporate, like, the,
the overall corporate team obviously, um, i- in terms of pre-planning and integration of, of financial systems and things like that, for
sure.
Um- Mm-hmm ... there's, there's a lot of planning, uh, that goes into
these things. But all of... You know, we're a decentralized model on an operating basis. So, you know, f- uh, Corey, uh, who comes from
Ease, he was CEO of Ease, he's running our Florida- Yeah ... operations. He's, he's the head. Think of him as the CEO of Florida.
Um, and we have that virtually in all these states that we have scaled.
And so, you know, his entire objective and, and goal is to integrate those businesses. You know, that's his entire focus. Um, and, you
know, these, these are successful businesses. The vast majority of these businesses were already successful, and if there was distress-
Hmm
it was because of the balance sheet. And so it's just kind of clean-
you know, cleaning up those balance sheet issues so that they can just focus on being operators and not have to worry about that side
of the business. So, um, yeah, there's, there's definitely a, a lot that goes into it. We have a really, uh, robust data analysis AI kind
of team, um, I think we're up to close to 60 people, uh, that's analyzing, you know, down to the store level, SKU level, uh, everything
all the time.
Um, so our... You know, what, what corporate's providing these kind
of local state leaders, they didn't have this, you know, this, this valuable kind of data to kind of optimize their businesses. So that's
really what we're providing, the kind of, the financial, um, you know, obviously the, the balance sheet relief, right?
We're, we're probably one of the only companies in the industry that's
getting institutional debt now. Uh, we've announced two recent debt deals. If you think the BMO, um- Hmm ... line that we got was SOFR
plus 175, which is like, that's straight institutional debt.
Jeremy Berke, Cultivated: Right.
Sam Armenia, Vireo Growth: Um, and then we just refied the property
in Florida and New York, which was, you know, we inherited at kind of 15% debt, and we just got eight and a half, uh, from an institutional,
uh, you know, from a, from a bank, a regional bank in, in the US.
So we're, you know, we're lowering the cost of capital, uh, we're making
their lives easier so they can just focus on being operators.
Jeremy Berke, Cultivated: I, I wanna talk about, uh, state markets,
geographies a little bit. Uh, Sam, you mentioned Florida. You know, it's a relatively restrictive or, you know, is restrictive-
Sam Armenia, Vireo Growth: Yeah ...
Jeremy Berke, Cultivated: uh, you know, limited license medical
market.
But you're also, you know, you have a huge presence in Colorado, which
is sort of the opposite of, of Florida in many ways. So, you know, how, how do those two bets fit together and, and, you know, what has
the team learned from operating in a, you know, I think you can call Colorado a mature market- Yeah, yeah
uh, versus Florida's medical market?
Sam Armenia, Vireo Growth: So w- I think we're most excited
about the mature markets, which I know is- Yeah ... counterintuitive to this industry.
Jeremy Berke, Cultivated: Sure. Yeah.
Sam Armenia, Vireo Growth: We, as a philosophy, we have a kind
of counter philosophy of what the industry's focused on, which is trying to protect kind of these limited license margins that exist in
these states, if you think of the New Jerseys or the Floridas and stuff like that, or the Ohios, the, you know, the recently- Mm-hmm
uh, you know, converted, uh, states. We believe that all of these states
are gonna normalize over time. You know, they're all gonna mature over time, and ultimately margins are gonna compress. And so we wanna
win in the competitive markets. If you can kind of generate a 20% EBITDA margin in a competitive market and own that market share, right?
Makes sense. Yeah. It's, it's about EBITDA dollars. It's not about-
Yeah ... EBITDA margin. So if you think of what we did in Colorado, we took the four, uh, largest operators in that state, um, with, uh,
Livewell, like Pharmacan's, uh, op- Mm ... operations, Green Dragon from Ease, uh, the Cannabis operations, and Schwaz's operations and,
and, you know, there's no one to compete with us in that state now, you know.
The fifth operator is now is in second, but it's, they, they don't
have the scale that we have. So what comes with that is obviously s- tremendous purchasing power when you have, you know, the largest
operations in the state by far. And, uh, you know, we have a few strategies in that state that are going fantastic.
We've just recently launched, um, a membership model, a new banner.
So we've consolidated a lot of the banners down, and we have one new banner, uh, called EDW, Everyday Weed, which is basically like low
price leader in the state. It's not disc- There's no- Yeah ... sales discounts. It's just everyday lowest price in the state.
We've launched cl- I think close to 30, uh, stores under that banner,
and what we're seeing, like both from a margin perspective, from a customer retention and repeat perspective, and basket size perspe-
perspective, like it's early, we're still converting a bunch of stores, but it, we're very optimistic about what we're, what we're doing
in Colorado.
And Colorado's our largest state, right, from a revenue perspective.
I think we're at like a 250 million run rate in that state. So you know, that, that state alone is like, you know, that could be its own,
you know, business i- in this industry. So, um, I think proving out the Colorado thesis Both for, for ourselves that we can kind of do
this in competitive markets.
But I think as we kind of show that, uh, story moving forward, I think
it's gonna get people comfortable with the idea that you can compete in, in competitive markets and win. And ultimately- Yeah ... if you
have the market share and you can capture enough, um, you know, EBITDA dollars, it doesn't really matter if you have 20...
Like in Nevada, we have 25% EBITDA margins in a very price compressed,
kind of mature market. But it ultimately doesn't matter because everybody's going to melt, right? And so- Right ... what would you rather...
The way I look at it is what would you rather be, a, a 20% EBITDA margin business that's gr- rapidly growing market share, or a 30% EBITDA
margin business that's trying desperately to hold on to those as, as it's a melting ice cube, right?
Because that's, we know where this is gonna go. We, you know, we talked
about Canada. Yeah. We know what, you know, a legalized kind of mature market ends up looking like, and so you have to win at that level,
you know? So I, it's d- it's obviously the opposite model of what most people are focused on, you know, especially from an investing perspective
in this industry.
Um, but we think ultimately we're playing a long-term game here, right?
And, you know, five, 10 years from now, if you're the biggest and you've won those markets and you have, you know, the, the largest market
share in the industry, um, you know, whether you're capturing 18, 20%, 22% EBITDA margin isn't really gonna matter.
It's gonna matter about the dollars. So that's our focus.
Jay Rosenthal, Cultivated: Um, I wanna, uh, that's a good shift
to, 'cause you said the word future. Um, uh, one, rescheduling of medical cannabis has happened. Rescheduling is sort of, I don't know,
I guess we'll hear when we hear something when we hear it. Um- Yeah ... what, what changes immediately- Yeah, it's
Sam Armenia, Vireo Growth: frustrating.
Jay Rosenthal, Cultivated: Yeah. What changes immediately for
Verio once, once an announcement comes down? Or is it sort of, you know, full steam ahead the way it is right now?
Sam Armenia, Vireo Growth: I think like most, it's the, it's
the tax, right? It's, it's the tax relief that we're, we're all desperately needing. As I mentioned, we kind of generated pre-tax earnings
already.
Um, you know, expect that to, to scale moving forward. But ultimately,
you know, we have a massive, uh, you know, tax provision from 280E, and so we have a net loss, right? And so when we're trying to attract,
you know, uh, institutional investors from, you know, outside of the cannabis space, ultimately generating earnings, I think Aaron Miles
mentioned this with you guys last week, right?
Yeah. Yeah, yeah. Like, ultimately generating earnings is gonna be
extremely important. So that, you know, that flip, anybody that's already generating pre-tax earnings becomes, you know, uh, you know,
positive earnings per share overnight. And, you know, that's, that's a huge flip for this industry. If you're not at pre-tax earnings
yet, if you don't, if you have an operating loss, or you have so much leverage that your, you know, interest expense, the cost to carry,
you know, eats your operating profit, then you have other things you've got to kind of work on and fix in this space, right?
But for, you know, I think for the Big Four for the most part, and
I'm including us now because we are the fourth with the billion-dollar, you know, revenue run rate. Um, and you know, we just, we just
guided to if those deals close, like 1.4 billion for Q1, uh, run rate in '27. So it's, um, you know, when you're at this scale, I think
the f- the, the four largest companies in the space, that kind of tax relief and that...
And then obviously understanding what do, what do we do with these
UTPs, right? Are we getting some sort of retroactive relief? If, if we don't get, you know, we're running out of time for '26, because
you need that 30 days- Right ... to get the final order. You know, we need the 25 days from the judge's recommendation to even get to,
uh, a final order.
So- Now we're into '27, assuming, uh, rescheduling the entire plant
happens. You know, is there any retroactive relief, or is it starting in '27? And then what do we all do with these UTPs is, you know,
it's gonna provide ... It's gonna be an important piece for investors to understand moving forward because, you know, these UTPs have,
have gotten, you know, out of control obviously.
Um, and it's everybody- Obviously you get ex- It's everybody in the
industry
Jay Rosenthal, Cultivated: You, you get, you get extra credit
points for actually, uh, referencing another person's interview on Cultivate- Yeah ... during your Cultivate interview. Not like-
Sam Armenia, Vireo Growth: Aaron's my buddy ...
Jay Rosenthal, Cultivated: he actually said-
Sam Armenia, Vireo Growth: So I always watch, I always watch
Aaron, uh, look- He's got a great mustache
Jeremy Berke, Cultivated: too.
Sam Armenia, Vireo Growth: So shout
Jeremy Berke, Cultivated: out to, uh-
Sam Armenia, Vireo Growth: He's just, he's just cool ... shout
out to Aaron. He's just cool. Yeah, he's cool. And what he's doing in Colorado, he's just, he's awesome. Um- He's
Jeremy Berke, Cultivated: good people. Um- Yeah,
Sam Armenia, Vireo Growth: he is. Absolutely.
Jeremy Berke, Cultivated: I- in, in the, uh, we just have a
few minutes left here, Sam. We're coming up on 30 minutes. Um, do you expect, you know, the pace of deals to, to, to continue, to stop?
I mean, how do you think about that looking into Q1 and Q2 of next
year? Like, is there a point where Vireo shifts to sort of just running the businesses that they've already acquired from acquiring businesses?
Or how is your team thinking about that?
Sam Armenia, Vireo Growth: I think we're thinking of both, to
be honest. Yeah.
Sure. Obviously, with our multiple where, with, uh, with our multiple
where it is, you know, to be frank, like, it, it, it does make it a bit more challenging. Um, like I said, we've done all these deals
at kind of $15 to $18. Right. So we can't start doing deals at six bucks. I mean- Right ... it's, you know, we started a buyback middle
of Q3.
We bought back two and a half million, uh, dollars in the, the last
six weeks of Q3. So right now we're kind of also looking at this in terms of maybe one of the best uses of our cash is to just buy ourselves,
'cause we're so cheap. Um, you know, or at least we think w- we're trading at a m- multiple that's, you know, too low for what we're building.
Um, and ultimately, you know, that's one way to allocate capital. But,
um, I don't think we're done. You know, John has been very clear in earnings calls and, and any, any time that he's been out there talking
that, um, you know, we still have a robust pipeline that we're working on, and, um, we're not done. We wanna scale all these states, right?
So that doesn't, you know... Will there be a pause? I know a lot of
maybe investors and/or analysts in the space are hoping for a pause so that we can kind of catch up, consolidate these things, and see
what the business is so that they can model this stuff. But, you know, we're not gonna, we're not gonna pause just because, right?
We're gonna, we're gonna still continue to, you know, um, try to allocate
capital, uh, the most efficient way that we can. And if there's, you know, a smart deal for us to do, we're gonna do it. Um, and so, you
know, we're not, we're certainly not done. I don't know if the pace can continue at the 17 deals- Right
in 22 months. Right. Age you. Um, you know, but-
Jeremy Berke, Cultivated: Yeah ...
Sam Armenia, Vireo Growth: we've now achieved at least the scale
that we needed, uh, in, in a, in a bunch of these states. Um, and but, you know, there, we still have the Marylands and the Illinois and,
and, you know, right now we only have the license in Pennsylvania. Like, there's, you know, there's still the Ohio deal still has to close.
Like, there's still a lot for us to accomplish, um, moving forward.
And I don't think even in the states that we have scaled, like Nevada, uh, Florida, Colorado, like, doesn't necessarily mean that we would
never r- you know, revisit even, you know, uh, scaling further there or further M&A moving forward. So-
Jeremy Berke, Cultivated: Yeah
Sam Armenia, Vireo Growth: um, it's ultimately about is it gonna
be accretive to the, to the, you know, to the shareholder? If it is, we're gonna do it. So, and, you know, we're in a bit of a different
position than I would say most operators in the space. Um, you know, we have, I think, 107 million of cash, but, you know, our net debt's
only 186, so it's kind of one times EBITDA to net debt.
Like, we are not over-levered in any way. Um, we've done a lot of these
deals by equitizing debt, right? So it's, it's- Mm-hmm ... you know, it's a way to kind of not... And I think that was one of the mistakes
that happened in the yesteryear of M&A, right? Where everybody took on all this debt to kind of make this M&A happen.
But, you know, you can't run three, four, five, six times, uh, you
know, EBITDA to net debt and, you know, the, the cost of capital is just too high in this industry. And the operating profit in this industry
is too low, right? Because even the leading operating profit margin in the space of, like, 15%, you know, there's a lot of debt in this
space that's 15%.
So you're basically giving it all to- Right ... you're giving it all
to the lenders. Right. Right? There's nothing left. Right. And that's before 288. That's before you're taxed. So it's, you gotta do the
math on this stuff, right? And- Right ... ultimately, if there's a way to acquire a business in a capital efficient manner where we see
that, you know, the, the bottom line's gonna, you know, improve for Virio, we're gonna do it.
Jay Rosenthal, Cultivated: Well, Sam, I really appreciate the
time on behalf of me and Jeremy. Yeah. And the team at Cultivated- It's great ... we appreciate it. Um, next time we have you on we'll
talk, well, about the deals that have closed, what's on the horizon, but also, um- Yeah ... what, what spring training looks like for
the Blue Jays. Um- Yeah.
Sam Armenia, Vireo Growth: By, by then hopefully we've done,
we've done some things that, you know- ... make 20, this 26-year kind of a thing of the past, 'cause it was torture.
Jeremy Berke, Cultivated: Yeah.
Jay Rosenthal, Cultivated: It was. It was, it was not, it was
not great. Uh, well- It was not great ... Vladi had eyes done, which I can't believe he hadn't done before. Um, he had his eye surgery
taken care of actually in Florida.
Um-
Sam Armenia, Vireo Growth: I saw
Jay Rosenthal, Cultivated: that ... um, we appreciate the time,
Sam, and we'll, we'll connect with you again. Appreciate it.
Sam Armenia, Vireo Growth: Thanks, guys. Thanks for having me.
Yep. Appreciate it.
Jay Rosenthal, Cultivated: Yep.
Jeremy Berke, Cultivated: Thanks so much, Sam.
---
On November 17, 2026, Sam Armenia, Vireo’s Director of Capital
Markets, made and/or reposted the below communications on his X account.


Additional Information and Where to Find It
In accordance with the Merger Agreement, Vireo filed with the SEC a
registration statement on Form S-4 (File No. 333-299395) (as amended, the “Registration Statement”), which includes a proxy
statement/prospectus that serves as both the proxy statement of Planet 13 for the solicitation of proxies from its stockholders for the
special meeting of Planet 13’s stockholders to be held on December 10, 2026 to vote on the Merger and other matters described in
the Registration Statement, and the prospectus relating to the offer and sale of the securities to be issued to Planet 13’s equity
holders in connection with the completion of the Merger. The Registration Statement was declared effective by the SEC on November 2, 2026,
and Vireo filed the definitive proxy statement/prospectus with the SEC pursuant to Rule 424(b)(3) under the Securities Act of 1933, as
amended, on November 2, 2026. Planet 13 also filed the definitive proxy statement/prospectus with the SEC as a definitive proxy statement
on Schedule 14A on November 2, 2026. Planet 13 commenced mailing the definitive proxy statement/prospectus on or about November 2, 2026
to its stockholders of record as of the close of business on October 29, 2026, the record date for the special meeting. Vireo and Planet
13 may also file other relevant materials with the SEC and applicable Canadian securities regulators regarding the Merger. This communication
is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Vireo or Planet
13 has filed or may file with the SEC or that has been or may be mailed to Planet 13 stockholders in connection with the Merger.
BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, PLANET 13 STOCKHOLDERS
ARE URGED TO CAREFULLY READ THE REGISTRATION STATEMENT AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS
THERETO) IN THEIR ENTIRETY, AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR INCORPORATED
BY REFERENCE INTO THE DEFINITIVE PROXY STATEMENT/PROSPECTUS, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT VIREO, PLANET
13 AND THE MERGER.
Any vote in respect of resolutions to be proposed at Planet 13’s
special meeting of stockholders to approve the Merger or other proposals in relation to the Merger should be made only on the basis of
the information contained in the definitive proxy statement/prospectus. You may obtain a free copy of the Registration Statement, the
definitive proxy statement/prospectus and other related documents filed with the SEC at the website maintained by the SEC at www.sec.gov
or by accessing the Investor Relations section of Planet 13’s website at https://investors.planet13.com/ or, for documents filed
by Vireo, by accessing Vireo’s website at www.vireogrowth.com under the tab “Investors”. Planet 13 stockholders may
also obtain copies of the definitive proxy statement/prospectus, or assistance with voting, by contacting Planet 13’s proxy solicitor,
Sodali & Co, toll-free at (800) 662-5200 or by email at PLNH@info.sodali.com. The information found on, or otherwise accessible through,
Vireo’s or Planet 13’s website is not incorporated by reference into, nor does it form a part of, this 425 or any other document
that Vireo or Planet 13 files with the SEC.
Participants in the Solicitation
Planet 13 and its directors and executive officers and certain of its
employees may be deemed to be participants in the solicitation of proxies from Planet 13’s stockholders in connection with the Merger.
Information regarding Planet 13’s directors and executive officers is set forth under the captions “Proposal No. 1: Election
of Directors,” “Corporate Governance,” “Executive Officers,” “Executive Compensation,” “Director
Compensation,” “Executive Compensation Tables,” and “Security Ownership of Certain Beneficial Owners and Management”
in the definitive proxy statement for Planet 13’s Annual General Meeting of Stockholders, filed with the SEC on April 29, 2026 (the
“Annual Meeting Proxy Statement”). To the extent the holdings of Planet 13’s securities by its directors or executive
officers have changed since the amounts set forth in the Annual Meeting Proxy Statement, such changes have been or will be reflected on
Forms 3, 4 and 5, filed with the SEC.
These documents may be obtained free of charge from the SEC’s
website at www.sec.gov or by accessing the Investor Relations section of Planet 13’s website at https://investors.planet13.com/.
Additional information regarding the interests of participants in the solicitation of proxies in connection with the transaction is contained
in the definitive proxy statement/prospectus and other relevant materials Planet 13 has filed or may file with the SEC and applicable
Canadian securities regulators.
Vireo, its directors, executive officers, other members of management,
and employees, under SEC rules, may be deemed participants in the solicitation of proxies of Planet 13’s stockholders in connection
with the Merger. A list of the names of such directors and executive officers and information regarding their interests in Vireo is contained
in the sections entitled “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”
and “Directors, Executive Officers and Corporate Governance” of Vireo’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2025, filed with the SEC on March 17, 2026, and which are available free of charge at the SEC’s website at www.sec.gov.
Additional information regarding the interests of such participants is contained in the Registration Statement and the definitive proxy
statement/prospectus.
No Offer or Solicitation
This Form 425 is not intended to and shall not constitute an offer
to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there
be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made in the United
States absent registration under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption
from, or in a transaction not subject to, such registration requirements. No offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act. No securities commission or securities regulatory authority in the United
States or any other jurisdiction has in any way passed upon the merits of the Merger or the accuracy or adequacy of this communication.
Forward-Looking Information
This Form 425 contains “forward-looking information” or
“forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred
to herein as “forward-looking information”). Forward-looking information contained in this Form 425 may be identified by the
use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,”
“may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject
to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements
regarding expectations around the proposed Merger and the expected timing and benefits thereof; the special meeting of Planet 13’s
stockholders to be held on December 10, 2026, including any adjournment or postponement thereof, and the receipt of the required approvals
of Planet 13’s stockholders, including minority approval under Multilateral Instrument 61-101; the expected closing date; the approximate
value of the consideration to be paid in the Merger; the satisfaction or waiver of the closing conditions set out in the Merger Agreement,
including receipt of all regulatory approvals; the expectation that the shares of Planet 13 common stock will be delisted from the Canadian
Securities Exchange and OTCQX Market and that Planet 13 will cease to be a reporting issuer under applicable U.S. and Canadian securities
laws; and Vireo’s expectations around integration of the operations of its recent and announced acquisitions and timing thereof.
These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and
unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Vireo, Planet 13 or
their respective subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by
the forward-looking statements or information contained in this Form 425. Forward-looking information is based upon a number of estimates
and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of
trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in
respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals
and permits.
Although Vireo and Planet 13 believe that the expectations and assumptions
on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information
because neither Vireo nor Planet 13 can give any assurance that they will prove to be correct. Actual results and developments may differ
materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties
that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and
uncertainties include, but are not limited to: the risk that the required approvals of Planet 13’s stockholders, including minority
approval under Multilateral Instrument 61-101, are not obtained, or that the special meeting is adjourned or postponed; risks related
to receipt of necessary regulatory and third-party approvals for completion of the proposed Merger; the occurrence of any event, change
or other circumstance that could give rise to the termination of the Merger Agreement, including circumstances requiring a party to pay
a termination fee; the risk that the Merger is not completed by the outside date set out in the Merger Agreement, as it may be extended;
risks and uncertainties associated with the proposed Merger, some of which are beyond Vireo’s and Planet 13’s control; Vireo’s
and Planet 13’s ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the
proposed Merger; the effects of the proposed Merger on Vireo, Planet 13 and the interests of various constituents; the nature, cost, impact
and outcome of pending and future litigation, including any litigation relating to the proposed Merger, other legal or regulatory proceedings,
or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where Vireo and
Planet 13 currently operate; current and future market conditions, including the market price of the subordinate voting shares of Vireo;
risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal
and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws
or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in
forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business;
liquidity and the ability of Vireo to raise additional financing to continue as a going concern; Vireo’s and Planet 13’s ability
to meet the demand for flower in their various markets; Vireo’s ability to dispose of its assets held for sale at an acceptable
price or at all; and risk factors set out in Vireo’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and Planet 13’s
Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission
at www.sec.gov and filed with the Canadian securities regulators and available under Vireo’s and Planet 13’s respective
profiles on SEDAR+ at www.sedarplus.com.
The statements in this Form 425 are made as of the date of this Form
425. Except as required by law, neither Vireo nor Planet 13 undertakes any obligation to update any forward-looking statements or forward-looking
information to reflect events or circumstances after the date of such statements.